Race Oncology Ltd has released a press release.
Zantrene Protects Mouse Hearts from Chemotherapy Damage
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Zantrene shows synergy with kinase inhibitors in melanoma
- Zantrene Improves Immune Therapy Treatment of Melanoma
- Race Oncology Announces On-Market Share Buyback
- EMD AML MDS Trial Expands to Europe
- Zantrene AML trial in Israel advances to Phase 2
Later from Racura Oncology
- Race Oncology: Quarterly Activity Report & Appendix 4C
- Race Oncology: RAC Quarterly Investor Presentation
- Race Oncology: Update - Notification of buy-back - RAC
- Race Initiates New Drug Discovery Program
- Race Develops Improved IV Formulation of Zantrene
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology